Jeffrey S. Wefel, PhD, ABPP
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. Wefel
Dr. Wefel is a board certified neuropsychologist, Professor with Tenure, and Neuropsychology Section Chief in the Department of Neuro -Oncology. He maintains an active consultation-liaison service where he conducts comprehensive neuropsychological assessments, presurgical fMRI of higher order cognitive function for neurosurgical planning, and offers interventions to adult cancer patients suffering from the central nervous system effects of cancer, cancer treatment, or other illnesses. He provides clinical and research mentoring as a Program Supervisor within the Neuropsychology Postdoctoral Fellowship program and hold an appointment as an Adjunct Clinical Assistant Professor in the Clinical Psychology graduate program at the University of Houston where he is involved in the training of Neuropsychology graduate students. Dr. Wefel's research activities seek to characterize the prevalence, pattern, course, risks, and biologic and neural substrates for the development of neurocognitive dysfunction associated with cancer and cancer therapies. Ultimately, this will lead to identification and testing of interventions to prevent and/or minimize cognitive dysfunction. He is the neurocognitive study chair on numerous cooperative group, industry sponsored and investigator initiated trials involving patients with breast cancer, brain tumor and brain metastasis, many of which integrate cognitive and neuroimaging outcomes as well as exploration of genetic moderators of cognitive and brain outcomes.
Present Title & Affiliation
Primary Appointment
Professor with Tenure, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief, Section of Neuropsychology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor with Tenure, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Associate Professor, Department of Psychology, University of Houston, Houston, TX
Education & Training
Degree-Granting Education
| 2002 | University of Houston, Houston, TX, USA, PhD, Clinical Psychology |
| 2000 | University of Houston, Houston, TX, USA, MA, Psychology |
| 1994 | Valparaiso University, Valparaiso, IN, USA, BS, Psychology |
Postgraduate Training
| 2002-2004 | Fellow, Clinical Neuropsychology, UT MD Anderson Cancer Center, Houston, TX |
| 2001-2002 | Intern, Clinical Neuropsychology, University of Chicago Medical Center, Chicago, IL |
Board Certifications
| 2011 | American Board of Professional Psychology, Board Certified in Clinical Neuropsychology |
Experience & Service
Academic Appointments
Associate Professor with Tenure, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2021
Associate Professor with Tenure, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2021
Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012
Other Appointments/Responsibilities
Member, National Brain Tumor Society, Steering Committee on Clinical Trials Endpoints, unknown, 2012 - Present
Member, National Brain Tumor Society, Medical Advisory Board, unknown, 2012 - Present
Member, NCI/CTEP Brain Metastasis in Breast Cancer Working Group, Unknown, 2009 - Present
Member, Response Assessment in Neuro-Oncology Group, Unknown, 2008 - Present
Founding and Steering Committee Member, International Cognition and Cancer Task Force, Unknown, 2006 - Present
Institutional Committee Activities
Office of Cancer Survivorship Faculty Reviewer, "NCCN Survivorship Guidelines - Cognitive Function", 2015 - Present
Work Group Faculty, “Primary Brain Lesion-Diffuse Glioma-Adult”, 2014 - Present
Work Group Faculty, “Brain Metastasis (1-3) Lesions”, 2014 - Present
Work Group Faculty, “Brain Metastasis greater than 3 Lesions”, 2014 - Present
Work Group Faculty, “Leptomeningeal Metastases”, 2014 - Present
Member, Psychosocial Council, 2013 - Present
Member, Gliogene Biospecimen Utilization Committee, 2012 - Present
Member, Survivorship Research Advisory Workgroup, 2012 - Present
Member, Faculty Senate, 2010 - 2016
Alternate Member, Credentials Committee of The Medical Staff, 2010 - 2012
Member, Cancer Survivorship Psychosocial Research Work Team, 2007 - 2019
Consultantships
Consultant, Angiochem Corporation, unknown, 2013 - 2025
Consultant, Actelion, unknown, 2012 - 2014
Consultant, Geron Corporation, Unknown, 2011 - 2013
Subject Matter Expert Reviewer, Lance Armstrong Foundation, unknown, 2011 - Present
Scientific Advisory Board, NeuroCog Trials, unknown, 2011 - 2012
Scientific Advisor, Eli Lilly, Unknown, 2010 - 2015
Neuropsychology Expert and Advisor, Genentech, Inc, Washington DC, 2009 - Present
Consultant, Exelixis, Inc, Unknown, 2009 - 2010
Consultant, F. Hoffman-La Roche Ltd, unknown, 2009 - Present
Scientific Advisory Board, Genentech, Inc, unknown, 2009 - 2016
Honors & Awards
| 2004 | Clinical Research Loan Repayment Program, National Institutes of Health |
| 2003 | Muriel D. Lezak Research Award, The Houston Neuropsychological Society |
| 2002 | Muriel D. Lezak Research Award, The Houston Neuropsychological Society |
| 2001 | Shell Foundation Graduate Scholarship, University of Houston |
| 1996 | Stella E. Cullen Scholarship, University of Houston |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology 26(5):617-624, 2017. e-Pub 2015. PMID: 26677053.
- Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschlag et al. Neuro Oncol 19(4):598-599, 2017. e-Pub 2017. PMID: 28339696.
- Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol 132(1):181-188, 2017. e-Pub 2017. PMID: 28116649.
- Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol 131(3):565-574, 2017. e-Pub 2016. PMID: 27848136.
- Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 18(12):1656-1663, 2016. e-Pub 2016. PMID: 27576872.
- Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol 128(2):323-31, 2016. e-Pub 2016. PMID: 27022915.
- Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep 6:25705, 2016. e-Pub 2016. PMID: 27168474.
- Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev 4:CD011376. e-Pub 2016. PMID: 27074263.
- Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34(9):945-52, 2016. e-Pub 2016. PMID: 26834058.
- Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol 17(3):e97-108, 2016. e-Pub 2016. PMID: 26972863.
- Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol 18 Suppl 2:ii13-ii20, 2016. PMID: 26989128.
- Noll KR, Weinberg JS, Ziu M, Wefel JS. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Arch Clin Neuropsychol 31(1):37-46, 2016. e-Pub 2015. PMID: 26537777.
- Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatment on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage 50(6):830-41, 2015. e-Pub 2015. PMID: 26344551.
- Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS. Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery 77(5):777-85, 2015. e-Pub 2015. PMID: 26317672.
- Noll KR, Wefel JS. Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function". Neuro Oncol 17(10):1421-2, 2015. PMID: 26395063.
- Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clin Cancer Res 21(14):3340-6, 2015. e-Pub 2015. PMID: 25904748.
- Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol 17(4):580-7, 2015. e-Pub 2014. PMID: 25227126.
- Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65(2):123-38, 2015. e-Pub 2014. PMID: 25483452.
- Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 23(6):626-33, 2014. e-Pub 2013. PMID: 24339329.
- Wefel JS, Kornet RL, Schagen SB. Systemically Treated Breast Cancer Patients and Controls: an Evaluation of the Presence of Noncredible Performance. J Int Neuropsychol Soc 20(4):1-13, 2014. e-Pub 2014. PMID: 24607070.
- Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav 7(4):501-10, 2013. e-Pub 2013. PMID: 23536015.
- Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 31(32):4076-84, 2013. e-Pub 2013. PMID: 24101048.
- Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D, Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429-37, 2013. e-Pub 2013. PMID: 23956241.
- Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A 110(28):11600-5, 2013. e-Pub 2013. PMID: 23798392.
- Taychakhoonavudh S, Franzini L, Lal L, Chang E, Meyers CA, Wefel JS, Swint JM. Comparison of patient reported outcomes (pros) and clinician reported outcomes (cros) in patients with metastatic brain disease. Value Health 16(3):A145-6, 2013. e-Pub 2013. PMID: 23693422.
- Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. J Clin Oncol 31(7):895-902, 2013. e-Pub 2013. PMID: 23341526.
- Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of Primary BrainTumor Patient and Caregiver Symptom Report. Cancer 118(20):5026-37, 2012. e-Pub 2012. PMID: 22415423.
- Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early Measures of Cognitive Function Predict Survival in Patients with Newly Diagnosed Glioblastoma. Neuro Oncol 14(6):808-16, 2012. e-Pub 2012. PMID: 22508762.
- Wefel JS, Schagen SB. Chemotherapy-Related Cognitive Dysfunction. Curr Neurol Neurosci Rep 12(3):267-75, 2012. e-Pub 2012. PMID: 22453825.
- Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 107(1):165-74, 2012. e-Pub 2011. PMID: 21964738.
- Schapiro R, Ferson D, Prabhu SS, Tummula S, Wefel J, Rao G. A Technique for Mapping Cortical Areas Associated with Speech Arrest. Stereotact Funct Neurosurg 90(2):118-123. e-Pub 2012. PMID: 22398728.
- Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive Function Before and After Surgery for Insular Gliomas. J Neurosurg 115(6):1115-25, 2011. e-Pub 2011. PMID: 21905800.
- Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703-8, 2011. e-Pub 2011. PMID: 21354373.
- van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583-93, 2011. e-Pub 2011. PMID: 21474379.
- Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(6):660-8, 2011. e-Pub 2011. PMID: 21558074.
- Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys 79(5):1487-95, 2011. e-Pub 2010. PMID: 20399573.
- Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13(3):353-61, 2011. e-Pub 2011. PMID: 21310734.
- Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER. Cognitive Impairment in Men with Testicular Cancer Prior to Adjuvant Therapy. Cancer 117(1):190-6, 2011. e-Pub 2010. PMID: 20737560.
- Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348-56, 2010. PMID: 20564075.
- Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery 146(6):1116-22, 2009. e-Pub 2009. PMID: 19879613.
- Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and Affective Sequelae of Primary Hyperparathyroidism and Early Response to Parathyroidectomy. J Int Neuropsychol Soc 15(6):1002-11, 2009. e-Pub 2009. PMID: 19807940.
- Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of Cognitive Decline in Hematopoietic Stem Cell Transplantation: A Within-subjects Design. Arch Clin Neuropsychol 24(7):689-98, 2009. e-Pub 2009. PMID: 19767298.
- Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037-44, 2009. e-Pub 2009. PMID: 19801201.
- Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-15, 2008. e-Pub 2008. PMID: 18316473.
- Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623-629, 2008. e-Pub 2007. PMID: 17974553.
- Mittendorf EA, Wefel JS, Meyers CA, Shapiro SE, Doherty DB, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract 13(4):338-44, 2007. PMID: 17669708.
- Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, 3rd, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60(2):277-83; discussion 283-4, 2007. PMID: 17290178.
- Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101(3):466-75, 2004. PMID: 15274059.
- Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292-9, 2004. PMID: 15160331.
- Atchison TA, Sanders A, Struchen M, Roebuck T, Wefel JS, High W, Contant C. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. Clin Neuropsychol 18(2):249-265, 2004. PMID: 15587672.
Invited Articles
- Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13(12):1285-1295, 2008. e-Pub 2008. PMID: 19019972.
- Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18(2):121-31, 2008. e-Pub 2008. PMID: 18415683.
- Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 13(4):362-9, 2006. PMID: 16858172.
- Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90(9):1691-6, 2004. PMID: 15150608.
Editorials
- Wefel JS Meyers CA. Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97(11):788-9, 2005. PMID: 15928294.
- Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557-8, 2003. PMID: 12913103.
Book Chapters
- Witgert ME, Wefel JS. The Neuropsychology of Oncology. In: Clinical Neuropsychology: A Pocket Handbook for Assessment. 3rd. APA: Washington DC, 2014.
- Cohen MZ, Shonka NA, Armstrong TS, Wefel JS. Cognitive Dysfunction. In: Cancer Symptom Management. 4th. Jones and Bartlett Learning: Burlington, CA, 2014.
- Noll KR, Wefel JS. Quality of Life and Neurocognitive Function. In: Neuro-Oncology: The Essentials. 3rd. Thieme Medical Publishers, Inc: New York, NY, 2014.
- Witgert ME, Wefel JS. Neuropsychological Assessment of Older Adults with a History of Cancer. In: Handbook on the Neuropsychology of Aging and Dementia. Springer: New York, 443-454, 2013.
- Meyers CA, Wefel JS. Cognitive Dysfunction. In: Cancer Symptom Science. Cambridge University Press: Cambridge, UK, 51-59, 2011.
- Witgert ME, Wefel JS. Neurobehavioral Side Effects of Cancer and Cancer Therapy. In: MD Anderson Manual of Psychosocial Oncology. McGraw-Hill: New York, 179-188, 2011.
- Brown PD, Laack NN, Wefel JS. Neurocognitive Effects. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practices of Oncology. 9th. Lippincott, Williams & Wilkins: Philadelphia, PA, 2011.
- Wefel JS, Armstrong TA, Kohli S. Neuropsychological Function, Symptom Measurement and Quality of Life in Brain Tumor Patients. In: Primary CNS Tumors: Pathogenesis and Therapy. Humana Press/Springer: New York, NY, 2010.
- Wefel JS, Collins RL, Kayl AE. Chemotherapy and Biological Response Modifier-Related Cognitive Dysfunction. In: Cognition and Cancer. Cambridge University Press: New York, 2009.
- Kayl AE, Collins RL, Wefel JS. Neuropsychological Assessment of Adults with Cancer. In: Cognition and Cancer. Cambridge University Press: New York, 2009.
- Smith JA, Wefel JS. Neurocognitive Testing in Clinical Trials. In: Cognition and Cancer. Cambridge University Press: New York, 2009.
- Meyers CA, Wefel JS. Quality of Life. In: Neuro-Oncology: The Essentials, 2nd Edition. M Bernstein, MS Berger: New York, 2008.
- Burton AW, Veramonti TL, Phan PC, Wefel JS,. Symptom Management for Patients with Brain Tumors: Improving Quality of Life. In: MD Anderson Cancer Center Series: Tumors of the Brain and Spine. Springer: New York, 2007.
- Wefel JS Janus T. Neurology and Neuropsychology in Oncology. In: Principles and Practice of Behavioral Neurology and Neuropsychology. P.M. Gordon Associates, Inc, 2003.
Grant & Contract Support
| Title: | A Phase II, Multi-Center, Open-Label Study Evaluating the Efficacy and Safety of GRN1005 In Non-Small Cell Lung Cancer Patients with Brain Metastases and, A Phase II, Multicenter, Open-Label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases |
| Funding Source: | Geron |
| Role: | Neurocognitive PI |
| Title: | A Brain Plasticity Based Computerized Intervention to Treat Attention and Memory Problems in Adult Brain Tumor Survivors, UTMDACC Cancer Survivorship Research Seed Money Grants |
| Funding Source: | UTMDACC Cancer Survivorship Research Seed Money |
| Role: | Principal Investigator |
| Title: | An International, Multi-Center, Randomized, Controlled, Double-Blinded, Phase III Efficacy Study of XL184 versus Lomustine in Subjects with Previously Treated Glioblastoma (Grade 4 Astrocytic Tumors) in First or Second Relapse |
| Funding Source: | Exelixis, Inc |
| Role: | Neurocognitive PI |
| Title: | A Neurocognitive substudy of BO21990, a randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma |
| Funding Source: | F. Hoffmann-La Roche Ltd |
| Role: | Neurocognitive PI |
| Title: | Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma |
| Funding Source: | Eli Lilly |
| Role: | Neurocognitive PI |
| Title: | Effects of Meditation on Cognitive Function and Quality of Life in Cancer |
| Funding Source: | UTMDACC Sister Institution Network Fund |
| Role: | Co-Principal Investigator |
| Title: | Multimodal MRI Biomarker of Mild Cognitive Impairment in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A Double-Blind, Placebo-Controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care+/-Continuous Bevacizumab Treatment Following Progression of Disease in Patients with Glioblastoma After First Line Treatment with Radiotherapy, Temozolomide and Bevacizumab |
| Funding Source: | F. Hoffman-La Roche Ltd |
| Role: | Neurocognitive Principal Investigator |
| Title: | A Phase II, Open-Label, Multi-center Study of ANG1005 in Patients with Recurrent High-Grade Glioma |
| Funding Source: | Angiochem Corporation |
| Role: | Neurocognitive Principal Investigator |
| Title: | A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer and Brain Metastases |
| Funding Source: | Translational Breast Cancer Research Consortium |
| Role: | Neurocognitive PI |
| Title: | A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER+2 Breast Cancer Patients with Progressive/Recurrent Brain Metastases |
| Funding Source: | Angiochem Corporation |
| Role: | Neurocognitive Principal Investigator |
| Title: | Inflammation-Induced CNS Glutamate During Breast Cancer Treatment |
| Funding Source: | NIH/NCI |
| Role: | Consultant |
| Title: | Will the Omega-3 Fatty Acid DHA Prevent Development of Cognitive-Dysfunction Due to Chemotherapy |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Consultant |
| Title: | SWOG S1827: Real Time Integrated Neurocognitive Function Study Evaluating Neurocognitive Function with the Clinical Trial Battery, NIH Biomarker, Imaging & Quality of Life Studies Funding Program |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A pilot study to determine the brain and cognitive effects of immune checkpoint inhibitor therapy in patients with melanoma as well as the association of this neurotoxicity with changes in cytokines and the fecal microbiome |
| Funding Source: | Institutional Research Grant Program at the University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator |
| Title: | Transforming the Standard of Care: A Personalized Approach for Patients with Cancer Metastatic to the Brain |
| Funding Source: | Brockman Foundation Grant |
| Role: | Co-Investigator |
| Title: | Real Time Integrated Neurocognitive Function Study Comparing Neurocognitive Function with the Clinical Trial Battery in Patients with High Brain Met Velocity Treated with SRS or SRS + HA-WBRT on NRG BN009 |
| Funding Source: | NIH Biomarker, Imaging, & Quality of Life Studies Funding Program |
| Role: | Principal Investigator |
| Title: | A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors, Clinical Trial Contract |
| Funding Source: | GT Medical Technology |
| Role: | Neurocognitive Principal Investigator |
| Title: | A virtually delivered exercise intervention to mitigate cognitive deficits from radiotherapy in AYAs with brain tumors |
| Funding Source: | Institutional Research Grant program at the University of Texas MD Anderson Cancer Center |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified August 15, 2024